bluebird bio, Inc. Contracts & Agreements

Master Services Agreement for Viral Vector Services, dated as of September 15, 2024, between the Registrant and Henogen SRL, as part of Thermo Fisher Scientific (Filed With SEC on November 14, 2024)

bluebird bio, Inc. 2023 Incentive Award Plan, as amended and restated, and forms of award agreements thereunder (Filed With SEC on November 14, 2024)

Description of the Registrant's Securities (Filed With SEC on September 13, 2024)

Amendment No. 3 to Patent and Know-How License Agreement No. 07554F33, dated October 29, 2014, by and between the Registrant (formerly known as Genetix, Inc.) and INSERM-TRANSFERT (Filed With SEC on September 13, 2024)

Amendment No. 4 to Patent and Know-How License Agreement No. 07554F33, dated December 16, 2015, by and between the Registrant (formerly known as Genetix, Inc.) and INSERM-TRANSFERT (Filed With SEC on September 13, 2024)

Amendment No. 6 to Clinical and Commercial Supply Agreement Viral Vector Product by and between the Registrant and SAFC Carlsbad, Inc (Filed With SEC on September 13, 2024)

Development and Manufacturing Services Agreement, dated February 28, 2012, by and between the Registrant and Minaris Regenerative Medicine, LLC (formerly known as Hitachi Advanced... (Filed With SEC on September 13, 2024)

Commercial Manufacturing Services Agreement, dated November 3, 2017, by and between the Registrant and Thermo Fisher (successor in interest to Henogen SA) (Filed With SEC on September 13, 2024)

Form of Performance-Based Restricted Stock Unit Agreement under the bluebird bio, Inc. 2023 Incentive Award Plan (Filed With SEC on September 13, 2024)

Non-Employee Director Compensation Policy (Filed With SEC on September 13, 2024)

Fourth Amendment to Loan and Security Agreement, dated as of August 29, 2024, by and among the Company, the several banks and other financial institutions or entities party... (Filed With SEC on August 30, 2024)

Form of Warrant Agreement (Filed With SEC on August 14, 2024)

Form of Warrant Agreement Amendment (Filed With SEC on August 14, 2024)

Third Amendment to Loan and Security Agreement, dated as of August 13, 2024, by and among the Company, the several banks and other financial institutions or entities party... (Filed With SEC on August 14, 2024)

Second Amendment to Loan and Security Agreement, dated as of July 9, 2024, by and among the Company, the several banks and other financial institutions or entities party thereto,... (Filed With SEC on July 11, 2024)

Employment Agreement, dated as of May 28, 2024, by and between bluebird bio, Inc. and O. James Sterling (Filed With SEC on May 29, 2024)

Loan and Security Agreement, dated as of March 15, 2024, by and among the Company, the several banks and other financial institutions or entities party thereto, as lenders, and... (Filed With SEC on May 3, 2024)

First Amendment to Loan and Security Agreement, dated as of April 30, 2024, by and among the Company, the several banks and other financial institutions or entities party thereto,... (Filed With SEC on May 3, 2024)

Underwriting Agreement, dated as of December 19, 2023, by and among bluebird bio, Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC (Filed With SEC on December 20, 2023)

Invoice Purchase and Sale Agreement, dated as of December 14, 2023, by and between bluebird bio, Inc. and Alterna Capital Solutions LLC (Filed With SEC on December 18, 2023)

Second Amendment to Master Manufacturing Services Agreement, dated September 21, 2023, by and between the Registrant and Lonza Houston, Inc (Filed With SEC on November 7, 2023)

Asset Purchase Agreement, dated as of October 26, 2023, by and between bluebird bio, Inc. and Novartis Pharma AG (Filed With SEC on October 30, 2023)

Sales Agreement, dated as of August 8, 2023, by and between bluebird bio, Inc. and Jefferies LLC (Filed With SEC on August 8, 2023)

Master Manufacturing Services Agreement, dated June 3, 2016, by and between the Registrant and Lonza Houston, Inc (Filed With SEC on March 29, 2023)

Amendment to Master Manufacturing Services Agreement, dated (Filed With SEC on March 29, 2023)

Employment Agreement, dated October 31, 2022, by and between the Registrant and Richard Colvin (Filed With SEC on March 29, 2023)

Employment Agreement, dated January 1, 2023, by and between the Registrant and Joseph Vittiglio (Filed With SEC on March 29, 2023)

Non-Employee Director Compensation Policy (Filed With SEC on March 29, 2023)

Underwriting Agreement, dated as of January 18, 2023, by and among bluebird bio, Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC (Filed With SEC on January 19, 2023)

Asset Purchase Agreement, dated as of January 5, 2023, by and between bluebird bio, Inc. and Bristol-Myers Squibb Company (Filed With SEC on January 6, 2023)

Asset Purchase Agreement, dated as of November 29, 2022, by and between bluebird bio, Inc. and argenx BV (Filed With SEC on November 30, 2022)

Amendment No (Filed With SEC on November 7, 2022)

Separation Agreement, dated as of September 12, 2022, by and between bluebird bio, Inc. and Jason F. Cole (Filed With SEC on November 7, 2022)

Consulting Agreement, dated as of September 12, 2022, by and between bluebird bio, Inc. and Jason F. Cole (Filed With SEC on November 7, 2022)

Consulting Agreement, dated May 26, 2022, by and between bluebird bio, Inc. and Danforth Advisors, LLC, as amended (Filed With SEC on November 7, 2022)

Sublease, dated October 31, 2022, by and between Finch Therapeutics, Inc. and bluebird bio, Inc (Filed With SEC on November 7, 2022)

Employment Agreement, dated October 17, 2022, by and between bluebird bio, Inc. and Christopher Krawtschuk (Filed With SEC on November 7, 2022)

Amendment No. 4 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc (Filed With SEC on August 4, 2022)

Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant (Filed With SEC on August 4, 2022)

Equity Distribution Agreement, dated as of June 22, 2022, by and between bluebird bio, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on June 22, 2022)

Employment Agreement, dated January 7, 2021, by and between the Registrant and Andrew Obenshain (Filed With SEC on March 4, 2022)

Employment Agreement, dated June 1, 2021, by and between the Registrant and Gina Consylman (Filed With SEC on March 4, 2022)

Employment Agreement, dated April 20, 2021, by and between the Registrant and Thomas Klima (Filed With SEC on March 4, 2022)

Employment Agreement, dated June 14, 2021, by and between the Registrant and Anne-Virginie Eggimann (Filed With SEC on March 4, 2022)

Offer Letter, dated October 1, 2019, by and between the Registrant and Jessica Whitten (Filed With SEC on March 4, 2022)

Sub-sublease Agreement, by and between the Registrant and Meta Platforms, Inc (Filed With SEC on March 4, 2022)

Office Lease Agreement, dated November 2, 2021 (Filed With SEC on November 5, 2021)

Securities Purchase Agreement, dated September 7, 2021, by and among the Registrant and the institutional investors named therein (Filed With SEC on November 5, 2021)

Registration Rights Agreement, dated September 7, 2021, by and among the Registrant and the persons listed on the attached Schedule A thereto (Filed With SEC on November 5, 2021)

Separation Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (Filed With SEC on November 4, 2021)

Tax Matters Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (Filed With SEC on November 4, 2021)

Employee Matters Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (Filed With SEC on November 4, 2021)

Intellectual Property License Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (Filed With SEC on November 4, 2021)

Transition Services Agreement, dated as of November 3, 2021, by and between bluebird bio, Inc. and 2seventy bio, Inc (Filed With SEC on November 4, 2021)

Transition Services Agreement, dated as of November 3, 2021, by and between 2seventy bio, Inc. and bluebird bio, Inc (Filed With SEC on November 4, 2021)

Form of Pre-Funded Warrant (Filed With SEC on September 8, 2021)

Securities Purchase Agreement, dated September 7, 2021, by and among the Company and the institutional investors named therein (Filed With SEC on September 8, 2021)

Registration Rights Agreement, dated September 7, 2021, by and between the Company and the persons listed on the attached Schedule A thereto (Filed With SEC on September 8, 2021)

Amended and Restated License Agreement by and between the Registrant and Celgene Corporation, dated February 16, 2016 (Filed With SEC on August 9, 2021)

License Agreement by and between the Registrant and Biogen Idec MA Inc., dated August 13, 2014 (Filed With SEC on August 9, 2021)

Exclusive Patent License Agreement by and between the Registrant and the National Institutes of Health, dated August 31, 2015 (Filed With SEC on August 9, 2021)

Description of the Registrant's Securities (Filed With SEC on February 23, 2021)

Amendment No. 3 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc (Filed With SEC on February 23, 2021)

Second Amended and Restated License Agreement by and between the Registrant and Celgene Corporation and Celgene European Investment Company LLC, dated May 8, 2020 (Filed With SEC on August 5, 2020)

First Amendment to Amended and Restated Co-Development, Co-Promote and Profit Share Agreement by and between the Registrant and Celgene Corporation and Celgene European Investment... (Filed With SEC on August 5, 2020)

Underwriting Agreement, dated as of May 18, 2020, among bluebird bio, Inc. and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the... (Filed With SEC on May 19, 2020)

Amendment Agreement No. 3 to the Toll Manufacturing and Service Agreement by and between bluebird bio (Switzerland) GmbH and Apceth Biopharma GmbH (Filed With SEC on March 12, 2020)

Description of the Registrant's Securities (Filed With SEC on February 18, 2020)

Amendment No. 2 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc (Filed With SEC on January 21, 2020)

Toll Manufacturing and Service Agreement, dated November 18, 2016 by and between the Registrant and APCETH Biopharma GmbH, as amended (Filed With SEC on August 1, 2019)

Clinical and Commercial Supply Agreement Viral Vector Product, dated November 27, 2017, by and between the Registrant and SAFC Carlsbad, Inc., as amended (Filed With SEC on August 1, 2019)

Sublease, dated April 16, 2019, by and between the Registrant and Aventis Inc (Filed With SEC on August 1, 2019)

Amendment to Sublease, dated April 19, 2019, by and between the Registrant and Aventis Inc (Filed With SEC on August 1, 2019)

License Agreement, dated December 23, 2015, by and between the Registrant and SIRION Biotech GmbH (Filed With SEC on February 21, 2019)

Toll Manufacturing and Service Agreement, dated November 18, 2016, by and between the Registrant and APCETH Biopharma GmbH (Filed With SEC on February 21, 2019)

Clinical and Commercial Supply Agreement Viral Vector Product, dated November 27, 2017, by and between the Registrant and SAFC Carlsbad, Inc (Filed With SEC on February 21, 2019)

Employment Agreement, dated December 18, 2018, by and between Bluebird and William (Chip) Baird (Filed With SEC on February 11, 2019)

Underwriting Agreement, dated as of July 24, 2018, among bluebird bio, Inc. and Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities... (Filed With SEC on July 25, 2018)

First Amendment of the Bluebird Bio, Inc. 2013 Employee Stock Purchase Plan (Filed With SEC on February 21, 2018)

Offer Letter, dated November 16, 2017, by and between the Registrant and Kory Wentworth (Filed With SEC on February 21, 2018)

Underwriting Agreement, dated as of December 12, 2017, among bluebird bio, Inc. and Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan... (Filed With SEC on December 13, 2017)

Amendment No. 2 to Amended and Restated Master Collaboration Agreement by and between the Registrant and Celgene Corporation, dated September 28, 2017 (Filed With SEC on November 1, 2017)

Amended and Restated License Agreement by and between the Registrant and Celgene Corporation, dated September 28, 2017 (Filed With SEC on November 1, 2017)

Letter Agreement by and between the Registrant and Biogen MA Inc., dated September 29, 2017 (Filed With SEC on November 1, 2017)

BLUEBIRDBIO, INC. 3,810,000 Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on June 28, 2017)

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE... (Filed With SEC on February 22, 2017)

AMENDMENT No. 2 TO EMPLOYMENT AGREEMENT (Filed With SEC on February 22, 2017)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on February 22, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on February 22, 2017)

SECOND AMENDMENT TO LEASE (Filed With SEC on February 22, 2017)

BLUEBIRDBIO, INC. 3,289,473 Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on December 7, 2016)

CONSENT TO ASSIGNMENT (Filed With SEC on November 2, 2016)

FIRST AMENDMENT TO LEASE (Filed With SEC on August 3, 2016)

Amendment No. 1 to Amended and Restated Master Collaboration Agreement (Filed With SEC on May 4, 2016)

Amended and Restated License Agreement by and between bluebird bio, Inc. and Celgene Corporation and Celgene European Investment Company LLC February 16, 2016 (Filed With SEC on May 4, 2016)

LICENSE AGREEMENT (Filed With SEC on May 4, 2016)

THE National Institutes of Health PATENT LICENSE AGREEMENT EXCLUSIVE COVER PAGE (Filed With SEC on May 4, 2016)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on May 4, 2016)

BLUEBIRD BIO, INC. 2,941,176Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on June 24, 2015)

AMENDMENT N4 TO THE LICENSE AGREEMENT (Filed With SEC on May 6, 2015)

TRANSITIONAL SERVICES AND SEPARATION AGREEMENT (Filed With SEC on May 6, 2015)

BLUEBIRD BIO, INC. 2,650,000Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on December 16, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2014)

Amendment to the Amended & Restated Investors Rights Agreement (Filed With SEC on August 12, 2014)

SECOND AMENDMENT TO LEASE (Filed With SEC on August 12, 2014)

BLUEBIRD BIO, INC. 3,000,000Shares of Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on July 9, 2014)

STOCK PURCHASE AGREEMENT BY AND AMONG BLUEBIRD BIO, INC., PRECISION GENOME ENGINEERING, INC., DR. ANDREW SCHARENBERG, M.D., AS REPRESENTATIVE, AND THE OTHER PERSONSLISTED ON THE... (Filed With SEC on June 30, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on May 13, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on March 5, 2014)

RIVERSIDE TECHNOLOGY CENTER AMENDED AND RESTATED LEASE AGREEMENT (Filed With SEC on November 14, 2013)

AMENDMENT N°3 TO THE LICENSE AGREEMENT (Filed With SEC on November 14, 2013)

BLUEBIRD BIO, INC. [] Sharesof Common Stock, par value $0.01 per share Underwriting Agreement (Filed With SEC on June 4, 2013)

BLUEBIRD BIO, INC. 2013 STOCKOPTION AND INCENTIVE PLAN (Filed With SEC on June 4, 2013)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 4, 2013)

BLUEBIRD BIO, INC. 2013 EMPLOYEESTOCK PURCHASE PLAN (Filed With SEC on June 4, 2013)

LEASE Between 150 SECOND STREET, LLC as Landlord, and BLUEBIRD BIO, INC. as Tenant, For Premises located at: 150 Second Street Cambridge, Massachusetts TABLE OF CONTENTS (Filed With SEC on June 4, 2013)

MASSACHUSETTS INSTITUTE OF TECHNOLOGY and INNOGENE PHARMACEUTICALS, INC. PATENT LICENSE AGREEMENT (EXCLUSIVE) -1- (Filed With SEC on May 21, 2013)

PATENT AND KNOW-HOW LICENSE AGREEMENT N° 07554F30 (Filed With SEC on May 21, 2013)

LICENSE AGREEMENT (Filed With SEC on May 21, 2013)

LICENSE AGREEMENT BETWEEN RESEARCH DEVELOPMENT FOUNDATION AND BLUEBIRD BIO, INC. (Filed With SEC on May 21, 2013)

NOVATION AGREEMENT (Filed With SEC on May 21, 2013)

Master Collaboration Agreement by and between bluebird bio, Inc. and Celgene Corporation March 19, 2013 (Filed With SEC on May 21, 2013)

FORM OF COMMON STOCK WARRANT (Filed With SEC on May 14, 2013)

FORM OF SERIES A-1 PREFERRED WARRANT (Filed With SEC on May 14, 2013)

FORM OF SERIES B PREFERRED WARRANT (Filed With SEC on May 14, 2013)

AMENDED AND RESTATED INVESTORS RIGHTSAGREEMENT (Filed With SEC on May 14, 2013)

AMENDMENT TO THE GENETIX PHARMACEUTICALS INC. 2002 EMPLOYEE, DIRECTORAND CONSULTANT STOCK PLAN (Filed With SEC on May 14, 2013)

BLUEBIRD BIO, INC. FOURTH AMENDMENT TO THE 2010 STOCK OPTION AND GRANT PLAN (Filed With SEC on May 14, 2013)

FORM OF INDEMNIFICATION AGREEMENT BLUEBIRD BIO, INC. Indemnification Agreement (Filed With SEC on May 14, 2013)

RIVERSIDE TECHNOLOGY CENTER AMENDED AND RESTATED LEASE AGREEMENT (Filed With SEC on May 14, 2013)

MASSACHUSETTS INSTITUTE OF TECHNOLOGY and INNOGENE PHARMACEUTICALS, INC. PATENT LICENSE AGREEMENT (EXCLUSIVE) -1- (Filed With SEC on May 14, 2013)

PATENT AND KNOW-HOW LICENSE AGREEMENT N° 07554F30 (Filed With SEC on May 14, 2013)

LICENSE AGREEMENT (Filed With SEC on May 14, 2013)

LICENSE AGREEMENT BETWEEN RESEARCH DEVELOPMENT FOUNDATION AND BLUEBIRD BIO, INC. (Filed With SEC on May 14, 2013)

NOVATION AGREEMENT (Filed With SEC on May 14, 2013)

Master Collaboration Agreement by and between bluebird bio, Inc. and Celgene Corporation March 19, 2013 (Filed With SEC on May 14, 2013)

BLUEBIRD BIO, INC. EXECUTIVE CASHINCENTIVE BONUS PLAN (Filed With SEC on May 14, 2013)

Category

Industry

Companies

Contracts

bluebird bio, Inc. Contracts & Agreements